Key Takeaways:
- Strong Start: Intuitive Surgical posted 17% total procedure growth in Q1 2026, with revenue rising 23% to $2.77 billion.
- Price Projection: Based on current assumptions, ISRG stock could reach $578.44 by December 2028.
- Potential Gains: That target implies a total return of 35.8% from the current price of $426.01.
- Annual Return: Investors could see roughly 13% annualized growth over the next 2.5 years.
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
Intuitive Surgical (ISRG) is the dominant player in robotic surgery — a market it essentially created and still leads by a wide margin. The stock is down about 20% from its 2025 high, creating what looks like a more reasonable entry point into a business that continues to grow steadily.
Q1 2026 was strong across the board.
- Da Vinci procedures grew 16% to 847,000.
- Ion — Intuitive’s lung biopsy platform — grew 39% to 43,000 procedures.
- Revenue grew 23%, and recurring revenue hit 86% of the total,
- Non-GAAP operating margin was 39%.
- Management raised its full-year procedure growth outlook to 13.5%-15.5%, up from the prior range of 13%-15%.
See analysts’ full growth forecasts and estimates for ISRG stock (It’s free) >>>
What the Model Says for Intuitive Surgical Stock
We analyzed Intuitive Surgical as a compounding business with a dominant installed base, a growing recurring revenue stream, and multiple platforms still in the early stages of adoption.
The central driver of near-term outperformance is da Vinci 5, the company’s newest surgical system. Utilization on da Vinci 5 is roughly 11% higher than the prior Xi model.
As more hospitals upgrade, that utilization gap flows directly into procedure volume and revenue. The installed base of da Vinci 5 systems has already reached nearly 1,500, with close to 13,000 surgeons using them.
Revenue is also growing faster than procedures — CFO Jamie Samath described it as “innovation-led revenue growth.”
In Q1, da Vinci revenue per procedure rose to approximately $1,880 from $1,780 a year ago. That increase reflects higher pricing for da Vinci 5, a growing mix of SP platform procedures, and Force Feedback instrumentation — tools that command premium pricing because they deliver genuinely better surgical outcomes.
Ion adds a second growth vector. A Mayo Clinic study published this quarter followed nearly 2,000 patients over five years and showed that early-stage lung cancer diagnoses increased from 46% to 69% when Ion was used — a 23% improvement. That kind of clinical data builds the case for broader hospital adoption and supports eventual expansion of reimbursement.
Looking further out, Intuitive is building what CEO Dave Rosa called a “flywheel” around data and AI. Da Vinci 5 captures surgical data at greater scale than any prior platform.
That data — combined with electronic medical records — feeds AI-enabled tools for anatomical identification, surgical decision support, and, eventually, aspects of automation. These aren’t near-term revenue drivers, but they represent a meaningful competitive moat that will be very difficult for any competitor to replicate.
Using a forecast of 14.2% annual revenue growth and 39% operating margins, with an exit P/E of 38x, our model projects ISRG reaching $578.44 by December 2028. That’s a 35.8% total return, or 13% annualized.
The 38x P/E assumption is a significant discount to ISRG’s one-year average of 51.9x, three-year average of 58.5x, and five-year average of 56.5x. The model assumes meaningful multiple compression from current 40x levels, which feels appropriate given the maturation of growth rates.
Our Valuation Assumptions
Estimate a company’s fair value instantly (Free with TIKR) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for ISRG stock:
1. Revenue Growth: 14.2%
ISRG grew revenue by 20.5% over the past year and compounded at 15.2% over five years.
The 14.2% assumption reflects a gradual moderation, as headwinds from China and Japan persist and GLP-1 drugs continue to weigh on bariatric procedure volumes.
The company’s own full-year procedure growth guidance of 13.5% to 15.5% anchors this assumption.
2. Operating margins: 39%
Trailing EBIT margins are 37.4%, already above the five-year average of 36.6%.
The 39% assumption reflects continued leverage of fixed costs as revenue scales, combined with improving product margins on the da Vinci 5 and Ion, both of which reached or approached corporate average contribution margins in Q1.
3. Exit P/E Multiple: 38x
ISRG currently trades at 40x forward earnings.
The model assumes modest compression to 38x — still a premium multiple, but below every historical average Intuitive has carried.
A quality business with durable growth, high recurring revenue, and expanding AI capabilities deserves a premium. But some moderation from peak multiples is prudent.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Here’s how ISRG stock could perform under different scenarios by December 2030:
- Low Case: With revenue growing at 11.1% and net income margins of 29.7%, investors could see a total return of 32.9% (6.5% annually).
- Mid Case: At 12.3% revenue growth and 31.9% net income margins, the total return climbs to 69.9% (12.5% annually).
- High Case: If revenue grows at 13.6% and margins reach 33.7%, total returns could hit 111% (18% annually).
See what analysts think about ISRG stock right now (Free with TIKR) >>>
The spread comes down to how quickly China and Japan normalize, how fast da Vinci 5 drives utilization gains across the global installed base, and whether Ion’s clinical momentum translates into meaningful procedure adoption at scale.
How Much Upside Does Intuitive Surgical Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
